The childhood malignancy neuroblastoma belongs to the group of embryonal tumors and originates from progenitor cells of the sympathoadrenal lineage. Treatment options for children with high-risk and relapsed disease are still very limited. In recent years, an ever-growing molecular diversity was identified using (epi)-genetic profiling of neuroblastoma tumors, indicating that molecularly targeted therapies could be a promising therapeutic option. In this review article, we summarize the various molecular subtypes and genetic events associated with neuroblastoma and describe recent advances in targeted therapies. We lay a strong emphasis on the importance of telomere maintenance mechanisms for understanding tumor progression and risk classification of neuroblastoma.(epi)-genetics, neuroblastoma, risk stratification, targeted therapies, telomere maintenance
| INTRODUCTIONNeuroblastoma, which is the most common extracranial solid tumor diagnosed in early childhood, belongs to the group of embryonal tumors and arises from developing cells of the sympathetic nervous system. 1,2 In principle, neuroblastomas can arise anywhere in the sympathetic nervous system. About 50% of the primary tumors manifest in the adrenal medulla. Other common sites of tumor formation are the sympathetic ganglia along the spine, in the abdomen or thorax. 1,2 Location of the primary tumor in the adrenal gland is associated with a worse prognosis than in sympathetic ganglia. 3 The mean age at diagnosis is 18 months. The clinical spectrum of neuroblastoma is highly diverse ranging from aggressive disease, often accompanied by therapy resistance, to low risk disease with complete spontaneous regression without therapeutic intervention in a subset of patients. 1,2 This multifaceted clinical presentation results from an underlying molecular diversity. Neuroblastomas can be classified based on the developmental origin, telomere maintenance mechanisms (TMMs) and/or the presence of certain recurrent genetic events. These different subtypes, molecular entities and groups have a different clinical prognosis and should be treated with specific molecularly targeted therapies in addition to conventional therapies. In this review, we describe the different molecular subtypes, their influence on risk stratification and describe novel approaches for targeted therapies. A special focus lies on recent developments on the role of telomere maintenance in neuroblastoma.
| DEVELOPMENTAL ORIGINThe super enhancer landscape and the associated transcription factor networks shape the epigenetic and transcriptomic profile of neuroblastoma cells and define cell identity. Based on these characteristic